New opportunities for accessing promising non-oncological orphan drugs
Saved in:
| Main Authors: | Carla E.M. Hollak, Carelle C. Reparon-Schuijt, Kathelijn Verdeyen, Lisa J. Deesker, Jaap W. Groothoff, Josephine M.I. Vos, Atse H. Huisman, Silvia van der Flier, Anke A.M.G. Pisters-van Roy |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | The Lancet Regional Health. Europe |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776225000675 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Application of four pricing models for orphan medicines: a case study for lumasiran
by: Noa Rosenberg, et al.
Published: (2024-12-01) -
Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01) -
EMA approved orphan medicines since the implementation of the orphan legislation
by: Eveliina Hahl, et al.
Published: (2025-06-01) -
Orphan Care in China
by: Liu Meng, et al.
Published: (2009-07-01) -
Orphan Care: An Introduction
by: Jo Daugherty Bailey
Published: (2009-07-01)